Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Immunologic Research
Published in: Immunologic Research 1/2017

01-02-2017 | Environment and Autoimmunity

HLA-DRB1 the notorious gene in the mosaic of autoimmunity

Authors: María-Teresa Arango, Carlo Perricone, Shaye Kivity, Enrica Cipriano, Fulvia Ceccarelli, Guido Valesini, Yehuda Shoenfeld

Published in: Immunologic Research | Issue 1/2017

Login to get access

Abstract

The major histocompatibility complex system is the most polymorphic gene cluster of the mammal genome. In humans, this is a genomic locus known as the human leukocyte antigen (HLA) system. The HLA encodes mostly immune-associated proteins whose main effect is the presentation of antigens to the immune cells. Thus, it is clear that it is essential for to the proper function of the immune response against pathogens and strongly implicated in the development of autoimmune diseases. Nonetheless, there are hundreds of polymorphisms of HLA-DRB1 which have been associated with different autoimmune disorders as well as with immune response to infection and vaccines. It is possible that the interaction of specific HLA with pathogenic antigens is one of the keys favoring (or protecting) toward the development of an autoimmune disease. In the era of personalized medicine, it would be of great help to build a map of the genomic risk of each individual to evaluate the risk of developing an autoimmune condition.
Literature
1.
2.
3.
4.
5.
6.
7.
8.
Shoenfeld Y, et al. The mosaic of autoimmunity: prediction, autoantibodies, and therapy in autoimmune diseases–2008. Isr Med Assoc J. 2008;10(1):13–9.PubMed
9.
10.
11.
12.
13.
14.
15.
Tomijenovic L, et al. Vaccination in autoimmune animal models. Isr Med Assoc J. 2014;16(10):657–8.PubMed
16.
17.
Kaufman JF, et al. The class II molecules of the human and murine major histocompatibility complex. Cell. 1984;36(1):1–13.PubMedCrossRef
18.
19.
Klein J, Figueroa F. Evolution of the major histocompatibility complex. Crit Rev Immunol. 1986;6(4):295–386.PubMed
20.
21.
22.
23.
24.
25.
26.
27.
de Vries N, et al. HLA-DR1 and rheumatoid arthritis in Israeli Jews: sequencing reveals that DRB1*0102 is the predominant HLA-DR1 subtype. Tissue Antigens. 1993;41(1):26–30.PubMedCrossRef
28.
Terao C, et al. Brief Report: main contribution of DRB1*04:05 among the shared epitope alleles and involvement of DRB1 amino acid position 57 in association with joint destruction in anti-citrullinated protein antibody-positive rheumatoid arthritis. Arthritis Rheumatol. 2015;67(7):1744–50. doi:10.​1002/​art.​39105.PubMedCrossRef
29.
30.
31.
32.
33.
34.
Nakken B, et al. Associations of MHC class II alleles in Norwegian primary Sjogren’s syndrome patients: implications for development of autoantibodies to the Ro52 autoantigen. Scand J Immunol. 2001;54(4):428–33.PubMedCrossRef
35.
Roitberg-Tambur A, et al. Molecular analysis of HLA class II genes in primary Sjogren’s syndrome. A study of Israeli Jewish and Greek non-Jewish patients. Hum Immunol. 1993;36(4):235–42.PubMedCrossRef
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
Deighton CM, et al. The contribution of HLA to rheumatoid arthritis. Clin Genet. 1989;36(3):178–82.PubMedCrossRef
50.
Stastny P, Fink CW. HLA-Dw4 in adult and juvenile rheumatoid arthritis. Transplant Proc. 1977;9(4):1863–6.PubMed
51.
52.
Gregersen PK, et al. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 1987;30(11):1205–13.PubMedCrossRef
53.
54.
Gonzalez-Gay MA, et al. Influence of human leukocyte antigen-DRB1 on the susceptibility and severity of rheumatoid arthritis. Semin Arthritis Rheum. 2002;31(6):355–60.PubMedCrossRef
55.
56.
Plant MJ, et al. Patterns of radiological progression in early rheumatoid arthritis: results of an 8 year prospective study. J Rheumatol. 1998;25(3):417–26.PubMed
57.
Weyand CM, Goronzy JJ. Disease mechanisms in rheumatoid arthritis: gene dosage effect of HLA-DR haplotypes. J Lab Clin Med. 1994;124(3):335–8.PubMed
58.
59.
60.
61.
Ling S, et al. The rheumatoid arthritis shared epitope triggers innate immune signaling via cell surface calreticulin. J Immunol. 2007;179(9):6359–67.PubMedCrossRef
62.
63.
64.
Terao C, et al. An association between amino acid position 74 of HLA-DRB1 and anti-citrullinated protein antibody levels in Japanese patients with anti-citrullinated protein antibody-positive rheumatoid arthritis. Arthritis Rheumatol. 2015;67(8):2038–45. doi:10.​1002/​art.​39133.PubMedCrossRef
65.
66.
Jiang X, et al. An Immunochip-based interaction study of contrasting interaction effects with smoking in ACPA-positive versus ACPA-negative rheumatoid arthritis. Rheumatology (Oxford). 2016;55(1):149–55. doi:10.​1093/​rheumatology/​kev285.CrossRef
67.
Moll JM, et al. Associations between ankylosing spondylitis, psoriatic arthritis, Reiter’s disease, the intestinal arthropathies, and Behcet’s syndrome. Medicine (Baltimore). 1974;53(5):343–64.CrossRef
68.
69.
70.
Martinez-Borra J, et al. HLA-B27 alone rather than B27-related class I haplotypes contributes to ankylosing spondylitis susceptibility. Hum Immunol. 2000;61(2):131–9.PubMedCrossRef
71.
Rubin LA, et al. Investigating the genetic basis for ankylosing spondylitis. Linkage studies with the major histocompatibility complex region. Arthritis Rheum. 1994;37(8):1212–20.PubMedCrossRef
72.
73.
Perez-Guijo V, et al. Distribution of HLA-DRB1 genes in patients with sporadic ankylosing spondylitis in the south of Spain. Joint Bone Spine. 2002;69(5):458–62.PubMedCrossRef
74.
Said-Nahal R, et al. The role of HLA genes in familial spondyloarthropathy: a comprehensive study of 70 multiplex families. Ann Rheum Dis. 2002;61(3):201–6.PubMedPubMedCentralCrossRef
75.
76.
Monowarul Islam SM, et al. HLA-DR8 and acute anterior uveitis in ankylosing spondylitis. Arthritis Rheum. 1995;38(4):547–50.PubMedCrossRef
77.
Breban M, et al. Animal models of the spondyloarthropathies. Curr Rheumatol Rep. 2000;2(4):282–7.PubMedCrossRef
78.
Reveille JD. The genetic contribution to the pathogenesis of rheumatoid arthritis. Curr Opin Rheumatol. 1998;10(3):187–200.PubMedCrossRef
79.
Rantapaa Dahlqvist S, et al. HLA antigens in rheumatoid arthritis patients with and without a family history of polyarthritis. Scand J Rheumatol. 1985;14(4):375–80.PubMedCrossRef
80.
81.
82.
83.
84.
85.
Tsao BP. Update on human systemic lupus erythematosus genetics. Curr Opin Rheumatol. 2004;16(5):513–21.PubMedCrossRef
86.
87.
Podrebarac TA, et al. Clinical correlates, serum autoantibodies and the role of the major histocompatibility complex in French Canadian and non-French Canadian Caucasians with SLE. Lupus. 1998;7(3):183–91.PubMedCrossRef
88.
89.
90.
91.
92.
Reveille JD, Arnett FC. The immunogenetics of Sjogren’s syndrome. Rheum Dis Clin North Am. 1992;18(3):539–50.PubMed
93.
94.
95.
Lessard CJ, et al. Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjogren’s syndrome. Nat Genet. 2013;45(11):1284–92. doi:10.​1038/​ng.​2792.PubMedCrossRef
96.
97.
Reveille JD, et al. Specific amino acid residues in the second hypervariable region of HLA-DQA1 and DQB1 chain genes promote the Ro (SS-A)/La (SS-B) autoantibody responses. J Immunol. 1991;146(11):3871–6.PubMed
98.
99.
Jean S, et al. DRB1*15 and DRB1*03 extended haplotype interaction in primary Sjogren’s syndrome genetic susceptibility. Clin Exp Rheumatol. 1998;16(6):725–8.PubMed
100.
Anaya JM, et al. TAP, HLA-DQB1, and HLA-DRB1 polymorphism in Colombian patients with primary Sjogren’s syndrome. Semin Arthritis Rheum. 2002;31(6):396–405.PubMedCrossRef
101.
Morling N, et al. Immunogenetics of rheumatoid arthritis and primary Sjogren’s syndrome: DNA polymorphism of HLA class II genes. Dis Markers. 1991;9(5):289–96.PubMed
102.
Kang HI, et al. Comparison of HLA class II genes in Caucasoid, Chinese, and Japanese patients with primary Sjogren’s syndrome. J Immunol. 1993;150(8 Pt 1):3615–23.PubMed
103.
Garcia Portales R, et al. Immunogenetics of the Sjogren’s syndrome in southern Spain. Ann Med Int. 1994;11(2):56–61.
104.
Price P, et al. The genetic basis for the association of the 8.1 ancestral haplotype (A1, B8, DR3) with multiple immunopathological diseases. Immunol Rev. 1999;167:257–74.PubMedCrossRef
105.
106.
Mavragani CP, et al. Sjogren’s syndrome: autoantibodies to cellular antigens. Clinical and molecular aspects. Int Arch Allergy Immunol. 2000;123(1):46–57.PubMedCrossRef
107.
Cooper GS, et al. The role of genetic factors in autoimmune disease: implications for environmental research. Environ Health Perspect. 1999;107(Suppl 5):693–700.PubMedPubMedCentralCrossRef
108.
Chinoy H, et al. In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. Arthritis Res Ther. 2006;8(1):R13. doi:10.​1186/​ar1862.PubMedCrossRef
109.
Love LA, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore). 1991;70(6):360–74.CrossRef
110.
Reed AM, et al. Immunogenetic studies in families of children with juvenile dermatomyositis. J Rheumatol. 1998;25(5):1000–2.PubMed
111.
Wedderburn LR, et al. HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis-scleroderma overlap. Rheumatology (Oxford). 2007;46(12):1786–91. doi:10.​1093/​rheumatology/​kem265.CrossRef
112.
Arnett FC, et al. Interrelationship of major histocompatibility complex class II alleles and autoantibodies in four ethnic groups with various forms of myositis. Arthritis Rheum. 1996;39(9):1507–18.PubMedCrossRef
113.
Arnett FC, et al. The Jo-1 antibody system in myositis: relationships to clinical features and HLA. J Rheumatol. 1981;8(6):925–30.PubMed
114.
O’Hanlon TP, et al. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1, and -DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies. Medicine (Baltimore). 2006;85(2):111–27. doi:10.​1097/​01.​md.​0000217525.​82287.​eb.CrossRef
115.
116.
117.
Rothwell S, et al. Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups. Ann Rheum Dis. 2015;. doi:10.​1136/​annrheumdis-2015-208119.PubMed
118.
119.
Hansen T, et al. Concordance for multiple sclerosis in Danish twins: an update of a nationwide study. Mult Scler. 2005;11(5):504–10.PubMedCrossRef
120.
121.
122.
123.
124.
125.
126.
127.
128.
129.
130.
131.
Marrosu MG, et al. Dissection of the HLA association with multiple sclerosis in the founder isolated population of Sardinia. Hum Mol Genet. 2001;10(25):2907–16.PubMedCrossRef
132.
133.
Saruhan-Direskeneli G, et al. HLA-DR and -DQ associations with multiple sclerosis in Turkey. Hum Immunol. 1997;55(1):59–65.PubMedCrossRef
134.
135.
136.
137.
138.
139.
Hasan ZN, et al. Association between human leukocyte antigen-DR and demylinating Guillain–Barre syndrome. Neurosciences (Riyadh). 2014;19(4):301–5.
140.
141.
Ma JJ, et al. HLA and T-cell receptor gene polymorphisms in Guillain–Barre syndrome. Neurology. 1998;51(2):379–84.PubMedCrossRef
142.
143.
144.
Hyttinen V, et al. Genetic liability of type 1 diabetes and the onset age among 22,650 young Finnish twin pairs: a nationwide follow-up study. Diabetes. 2003;52(4):1052–5.PubMedCrossRef
145.
Concannon P, et al. Type 1 diabetes: evidence for susceptibility loci from four genome-wide linkage scans in 1,435 multiplex families. Diabetes. 2005;54(10):2995–3001.PubMedCrossRef
146.
Rich SS. Mapping genes in diabetes. Genetic epidemiological perspective. Diabetes. 1990;39(11):1315–9.PubMedCrossRef
147.
Valdes AM, et al. HLA class II DR-DQ amino acids and insulin-dependent diabetes mellitus: application of the haplotype method. Am J Hum Genet. 1997;60(3):717–28.PubMedPubMedCentral
148.
Thomson G, et al. Genetic heterogeneity, modes of inheritance, and risk estimates for a joint study of Caucasians with insulin-dependent diabetes mellitus. Am J Hum Genet. 1988;43(6):799–816.PubMedPubMedCentral
149.
150.
Kawabata Y, et al. Asian-specific HLA haplotypes reveal heterogeneity of the contribution of HLA-DR and -DQ haplotypes to susceptibility to type 1 diabetes. Diabetes. 2002;51(2):545–51.PubMedCrossRef
151.
She JX. Susceptibility to type I diabetes: HLA-DQ and DR revisited. Immunol Today. 1996;17(7):323–9.PubMedCrossRef
152.
Todd JA, et al. The A3 allele of the HLA-DQA1 locus is associated with susceptibility to type 1 diabetes in Japanese. Proc Natl Acad Sci USA. 1990;87(3):1094–8.PubMedPubMedCentralCrossRef
153.
154.
155.
156.
Brix TH, et al. A population-based study of Graves’ disease in Danish twins. Clin Endocrinol (Oxf). 1998;48(4):397–400.CrossRef
157.
158.
159.
160.
Vaidya B, et al. CTLA4 gene and Graves’ disease: association of Graves’ disease with the CTLA4 exon 1 and intron 1 polymorphisms, but not with the promoter polymorphism. Clin Endocrinol (Oxf). 2003;58(6):732–5.CrossRef
161.
162.
163.
Heward JM, et al. Linkage disequilibrium between the human leukocyte antigen class II region of the major histocompatibility complex and Graves’ disease: replication using a population case control and family-based study. J Clin Endocrinol Metab. 1998;83(10):3394–7. doi:10.​1210/​jcem.​83.​10.​5137.PubMed
164.
Chen QY, et al. HLA-DRB1*08, DRB1*03/DRB3*0101, and DRB3*0202 are susceptibility genes for Graves’ disease in North American Caucasians, whereas DRB1*07 is protective. J Clin Endocrinol Metab. 1999;84(9):3182–6. doi:10.​1210/​jcem.​84.​9.​5991.PubMed
165.
166.
167.
Sawai Y, DeGroot LJ. Binding of human thyrotropin receptor peptides to a Graves’ disease-predisposing human leukocyte antigen class II molecule. J Clin Endocrinol Metab. 2000;85(3):1176–9. doi:10.​1210/​jcem.​85.​3.​6376.PubMed
168.
Ban Y, et al. The influence of human leucocyte antigen (HLA) genes on autoimmune thyroid disease (AITD): results of studies in HLA-DR3 positive AITD families. Clin Endocrinol (Oxf). 2002;57(1):81–8.CrossRef
169.
Katsuren E, et al. HLA class II alleles in Japanese patients with Graves’ disease: weak associations of HLA-DR and -DQ. Endocr J. 1994;41(6):599–603.PubMedCrossRef
170.
Onuma H, et al. Association of HLA-DPB1*0501 with early-onset Graves’ disease in Japanese. Hum Immunol. 1994;39(3):195–201.PubMedCrossRef
171.
172.
173.
174.
175.
Fox RI, et al. Synovial fluid lymphocytes differ from peripheral blood lymphocytes in patients with rheumatoid arthritis. J Immunol. 1982;128(1):351–4.PubMed
176.
Veys EM, et al. Determination of T lymphocyte subpopulations by monoclonal antibodies in rheumatoid arthritis. Influence of immunomodulating agents. Int J Immunopharmacol. 1981;3(3):313–9.PubMedCrossRef
177.
178.
179.
Moreno-Otero R, et al. Reduced numbers of CD8+ T cells and B cell-expression of Leu-8 antigen in peripheral blood of patients with primary biliary cirrhosis. Hepatogastroenterology. 1994;41(3):239–43.PubMed
180.
181.
LaFleur C, et al. HLA-DR antigen frequencies in Mexican patients with dengue virus infection: HLA-DR4 as a possible genetic resistance factor for dengue hemorrhagic fever. Hum Immunol. 2002;63(11):1039–44.PubMedCrossRef
182.
Han YN, et al. Relationship of human leukocyte antigen class II genes with the susceptibility to hepatitis B virus infection and the response to interferon in HBV-infected patients. World J Gastroenterol. 2005;11(36):5721–4.PubMedPubMedCentralCrossRef
183.
184.
185.
186.
187.
Gokhale P, et al. Variations in immunogenetics, human papillomavirus (HPV) infection & predisposition to cervical cancer in Indian women. Indian J Med Res. 2014;140(Suppl):S36–43.PubMedPubMedCentral
188.
Thanapati S, et al. Association of human leukocyte antigen class II allele and haplotypes in chikungunya viral infection in a western Indian population. Trans R Soc Trop Med Hyg. 2014;108(5):277–82. doi:10.​1093/​trstmh/​tru030.PubMedCrossRef
189.
190.
191.
192.
193.
194.
195.
196.
197.
198.
199.
200.
201.
Li Q, et al. Epstein-Barr virus uses HLA class II as a cofactor for infection of B lymphocytes. J Virol. 1997;71(6):4657–62.PubMedPubMedCentral
202.
Truedsson L, et al. Sharing of MHC haplotypes among patients with systemic lupus erythematosus from unrelated Caucasian multicase families: disease association with the extended haplotype [HLA-B8, SC01, DR17]. J Rheumatol. 1995;22(10):1852–61.PubMed
203.
Marchini M, et al. HLA class II antigens associated with lupus nephritis in Italian SLE patients. Hum Immunol. 2003;64(4):462–8.PubMedCrossRef
204.
205.
206.
207.
208.
Zandman-Goddard G, et al. A comparison of autoantibody production in asymptomatic and symptomatic women with silicone breast implants. J Rheumatol. 1999;26(1):73–7.PubMed
209.
Bar-Meir E, et al. Silicone gel breast implants and connective tissue disease—a comprehensive review. Autoimmunity. 2003;36(4):193–7.PubMedCrossRef
210.
211.
212.
213.
214.
215.
216.
217.
218.
219.
220.
221.
222.
Mineta M, et al. Contribution of HLA class I and class II alleles to the regulation of antibody production to hepatitis B surface antigen in humans. Int Immunol. 1996;8(4):525–31.PubMedCrossRef
223.
224.
225.
226.
227.
228.
229.
230.
Pan L, et al. A genome-wide association study identifies polymorphisms in the HLA-DR region associated with non-response to hepatitis B vaccination in Chinese Han populations. Hum Mol Genet. 2014;23(8):2210–9. doi:10.​1093/​hmg/​ddt586.PubMedCrossRef
231.
232.
233.
234.
Metadata
Title
HLA-DRB1 the notorious gene in the mosaic of autoimmunity
Authors
María-Teresa Arango
Carlo Perricone
Shaye Kivity
Enrica Cipriano
Fulvia Ceccarelli
Guido Valesini
Yehuda Shoenfeld
Publication date
01-02-2017
Publisher
Springer US
Published in
Immunologic Research / Issue 1/2017
Print ISSN: 0257-277X
Electronic ISSN: 1559-0755
DOI
https://doi.org/10.1007/s12026-016-8817-7

Other articles of this Issue 1/2017

Immunologic Research 1/2017 Go to the issue

GUEST EDITORIAL

Novel clinical and therapeutic aspects in autoimmunity

Mechanism in Autoimmunity

Diagnostic accuracy of two tests for determination of anti-m2 in the diagnosis of primary biliary cirrhosis: Is it possible to predict the course of the disease?

Mechanism in Autoimmunity

New automated indirect immunofluorescent antinuclear antibody testing compares well with established manual immunofluorescent screening and titration for antinuclear antibody on HEp-2 cells

Environment and Autoimmunity

Severe somatoform and dysautonomic syndromes after HPV vaccination: case series and review of literature

Mechanism in Autoimmunity

Cross-reactivity between annexin A2 and Beta-2-glycoprotein I in animal models of antiphospholipid syndrome

Erratum

Erratum to: Severe somatoform and dysautonomic syndromes after HPV vaccination: case series and review of literature